Vitamin D in Australia : issues and recommendations by Nowson, Caryl A. et al.
Deakin Research Online 
Deakin University’s institutional research repository 
DDeakin Research Online  
Research Online  
This is the published version (version of record) of: 
 
Nowson, Caryl A., Diamond, Terrence H., Pasco, Julie A., Mason, Rebecca 
S., Sambrook, Philip N. and Eisman, John A. 2004-03, Vitamin D in 
Australia: issues and recommendations, Australian family physician, vol. 
33, no. 3, pp. 133-138. 
 
Available from Deakin Research Online:  
 
http://hdl.handle.net/10536/DRO/DU:30002479 
 
 
Copyright to Australian Family Physician. Reproduced with 
permission. Permission to reproduce must be sought from the 
publisher, The Royal Australian College of General Practitioners. 
 
Copyright : ©2004, Australian Family Physician   
 
 
 
Vitamin D and health
There is increasing recognition that a significant number
of Australians and people from specific groups within
the community are suffering from vitamin D deficiency.
While the prevalence of vitamin D deficiency varies, it is
much higher than previously thought (Table 1). The
highest rates of hip fracture occur in women over 80
years of age,1 many of whom are at high risk of vitamin
D deficiency. Some studies suggest that mild vitamin D
deficiency (insufficiency) can occur at younger ages.2
Vitamin D compounds
Although a number of steroid compounds are classified
as vitamin D, for practical reasons this generic term is
generally applied to the following two molecules:
• cholecalciferol (vitamin D3) – formed through the
action of ultraviolet light on 7-dehydrocholesterol in
the skin of animals and humans to form provitamin
D3 which is converted by a thermic reaction to
form cholecalciferol, and
• ergocalciferol (vitamin D2) – a rarer form of vitamin
D, produced by ultraviolet irradiation of the plant
steroid ergosterol. This form of vitamin D is used in
some supplemental products.
Vitamin D3 and vitamin D2, made in the skin and/or ingested,
are transported to the liver and metabolised to 25-hydroxyvit-
amin D (25OHD), the major circulating form (Figure 1).
Further hydroxylation occurs in the kidneys to form the bio-
logically active calcitriol, also known as 1,25 dihydroxyvitamin
D (1,25(OH)2D), which is transported in the blood bound to
albumin and vitamin D binding protein. Only a small fraction
of the 1,25(OH)2D circulates in its ‘free’ form to bind to a spe-
cific vitamin D receptor (VDR). The binding of 1,25(OH)2D to
its receptor regulates calcium and phosphate metabolism
and induces a wide array of biological responses.
BACKGROUND A significant number of
Australians and people from specific groups
within the community are suffering from vitamin
D deficiency. It is no longer acceptable to assume
that all people in Australia receive adequate
vitamin D from casual exposure to sunlight.
OBJECTIVE This article provides information on
causes, consequences, treatment and prevention
of vitamin D deficiency in Australia. 
DISCUSSION People at high risk of vitamin D
deficiency include the elderly, those with skin
conditions where avoidance of sunlight is
required, dark skinned people (particularly
women during pregnancy or if veiled) and
patients with malabsorption, 
eg. coeliac disease. For most people, deficiency
can be prevented by 5–15 minutes exposure of
face and upper limbs to sunlight 4–6 times per
week. If this is not possible then a vitamin D
supplement of at least 400 IU* per day is
recommended. In cases of established vitamin D
deficiency, supplementation with 3000-5000 IU
per day for at least 1 month is required to replete
body stores. Increased availability of larger dose
preparations of cholecalciferol would be a useful
therapy in the case of severe deficiencies.
* 40 IU (international units) = 1 µg
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Bones • THEME
Actions of calcitriol
• Increases absorption of calcium and phosphate
from the small intestine. This is possibly the most
important function of vitamin D compounds3
• Maintains calcium homeostasis in the extracellular fluid
directly and in interaction with parathyroid hormone (PTH)
• Through its feedback mechanism, regulates its own
renal production and degradation
• Facilitates skeletal mineralisation largely through enhanc-
ing acquisition of environmental mineral from the diet
• Stimulates bone resorption, particularly at high 
concentrations.
Normal bone remodelling
In order to highlight the importance of vitamin D defi-
ciency on bone turnover, it is important to understand
the normal bone remodelling cycle. The remodelling
process starts when osteoclasts resorb existing bone.
Thereafter, a team of newly differentiated osteoblasts is
recruited on the bone surface to synthesise unminer-
alised bone matrix called osteoid. In the presence of
adequate 1,25(OH)2D and mineral, the osteoblasts min-
eralise the osteoid. The mineralisation process occurs in
two phases – a rapid first phase taking a few days and a
prolonged second phase lasting up to 6 months.
Vitamin D deficiency and bone
Both plasma 25OHD and 1,25(OH)2D levels have been
shown to decrease with age. This may occur as a result of
age related factors such as reduced capacity to produce
vitamin D, diminished sunlight exposure,4 reduced intake
and decline in renal function and secondary causes (Table
2). Vitamin D insufficiency where serum 25OHD concen-
trations are between 25–50 nmol/L may lead to a
progressive increase in PTH secretion, high bone turnover,
increased age related bone loss and an increased risk of
developing osteoporosis. Low vitamin D status has been
associated with reduced bone mineral density,8 high bone
turnover5 and increased risk of hip fracture in the elderly.6,7
Osteomalacia, on the other hand, is the bone disease
seen in true vitamin D deficiency. In more severe cases,
with serum 25OHD levels usually less than 12.5 nmol/L,
patients often present with bone and muscle pain, weak-
ness and pseudofractures (ie. stress fracture where the
fracture line does not breach the cortex completely). On
bone histomorphometry, the classic findings of hyperos-
teoidosis, thickened unmineralised seams, increased
osteoclast surfaces and tetracycline smearing are
evident. Due to the chronicity of this disorder, progres-
sive bone loss is often evident and osteoporosis coexists.
Table 3 classifies the stages of vitamin D deficiency.
Vitamin D deficiency,
muscle function and falls
Falls are a crucial part of the pathogenesis of osteoporotic
fractures. Vitamin D deficiency has been demonstrated to
be an independent predictor of falls in the elderly. The
findings that 1,25(OH)2D may affect skeletal muscle
function have gained much attention in recent years.
In osteomalacia, a metabolic myopathy has been
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Table 1. Australian high risk population groups with low serum
25OHD levels as reported in the literature
Highest risk groups Prevalence of deficiency*
Residential care elderly in high level care 55%34
Residential care elderly in high and low level care 68–86%35
Residential care elderly in low level care 22%34
Geriatric admissions to hospital 67%36
Patients with hip fracture 61%40
63%**6
Dark skinned women (particularly veiled) >80%**37,38
Mothers of infants with rickets 80%39
(particularly dark skinned and veiled)
Lower risk groups
Community dwelling elderly 17%36
Women in winter 80+ years 22%2
60–79 years 12%2
20–59 years 8%2
* Deficiency defined as either <25 or 28 nmol/L
** Deficiency defined as <50 nmol/L
Table 2. Causes of vitamin D deficiency
• Reduced intake or synthesis of cholecalciferol
– reduced sunlight exposure
– reduced synthesis from a given UV exposure
– low consumption of foods with high vitamin D content
• Disorders associated with abnormal gut function
– small bowel disorders – coeliac disease (note: a common presentation
for primary diagnosis of coeliac disease is the presence of osteoporosis
with low vitamin D levels), sprue, inflammatory bowel disorders,
infiltrative disorders such as lymphoma, granuloma, amyloid, small
bowel resection
– pancreatic insufficiency – chronic pancreatitis, cystic fibrosis
– biliary obstruction – primary biliary cirrhosis, external biliary drainage
• Reduced synthesis or enhanced degradation of 25OHD
– chronic hepatic disorders – hepatitis, cirrhosis
noted, consisting histologically of atrophied type 2
muscle fibres with fat infiltration, fibrosis and glycogen
granules. Patients present typically with gait distur-
bances and difficulties arising from a chair. Abnormal
motor performance, increased body sway and quadri-
ceps weakness have been reported with serum
25OHD levels below 20–30 nmol/L in elderly men and
veiled Arab women.9,10 A randomised controlled trial
demonstrated a 49% reduction in falls associated with
vitamin D and calcium treatment.11 Furthermore, poly-
morphisms in the VDR genotypes have been
associated with reduced quadriceps muscle function.12
These findings suggest a link between vitamin D defi-
ciency, falls and bone fragility fractures.
Other potential effects of low 
vitamin D status
The receptor for 1,25(OH)2D has been discovered in
most nucleated cells of the body, which suggests that
vitamin D could play an important role in a number of
physiological processes. Vitamin D deficiency has been
reported to result in impaired immune function, including
reduced capacity to respond to agents that cause tuber-
culosis.13 In addition 1,25(OH)2D has been shown to
possess antiproliferative and prodifferentiating effects on
several other types of cells present in the skin.14
Sources of vitamin D
The main source of vitamin D for Australians is expo-
sure to sunlight. In Australians there are seasonal
variations in vitamin D status, such that serum 25OHD
levels are somewhat lower at the end of winter com-
pared to the end of summer. It has been estimated
that exposure of the entire body surface to around
10–15 minutes noonday sun in summer (ie. around 
1 minimal erythemal dose) is comparable to taking
around 15 000 IU of vitamin D orally.4 Less vitamin D
would be synthesised at other times of the day, in
winter, and in those with dark skin or the elderly.
Vitamin D3 is found in small quantities in few foods.
Rich sources of vitamin D are fish, especially high fat fish
such as salmon, herring and mackerel. Other sources are
meat, eggs and fortified foods such as margarine.
Margarine is the only food in Australia that is widely used
that contains significant amounts of vitamin D through for-
tification. Adequate vitamin D is unlikely to be achieved
through dietary means alone for most Australians with esti-
mated daily vitamin D intake for adults between 80–120
IU. Extending fortification of the food supply would result
in a modest increase in dietary vitamin D intake, taking
average intakes to around 200 IU per day, and although
this may assist in maintaining vitamin D status in low risk
groups, it would not be sufficient to maintain adequate
vitamin D status in high risk groups.15 In Australia there is
no current recommended dietary intake level set for
vitamin D, but 200 IU has been proposed for the elderly
not exposed to at least 2 hours of direct sunlight per
week.16 Recently the Food and Nutrition Board of the US
Institute of Medicine proposed a daily reference intake of
200 IU (0–50 years), 400 IU (51–70 years), and 600 IU (71+
years).17 This represents a tripling of the recommended
intake for those over 70 years of age. 
Sunscreens
Broad spectrum sunscreens protect the skin against
UV-A (320–400 nm) and UV-B (290–320 nm) radiation.
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Figure 1. Absorption and metabolism of vitamin D15 
© 2002. The Medical Journal of Australia. Reproduced with permission 
Table 3. Stages of vitamin D deficiency
Severity Serum 25OHD Serum PTH Bone
(nmol/L) (% increase) turnover
Mild 25–50 15 High normal
(insufficiency)
Moderate 12.5–25.0 15–30 High
Severe <12.5 >30 Osteomalacia
Radiation in the UV-B range is responsible for skin car-
cinogenesis as well  as conversion of
7-dehydrocholesterol into provitamin D3.4 The applica-
tion of sun protection factor (SPF) 8 has been reported
to reduce the amount of vitamin D synthesised from a
given dose of UV by more than 95%.18 For this reason,
concerns were raised that the use of sunscreens for
the prevention of skin cancer may cause vitamin D
deficiency, especially among the elderly. Yet sun-
screens are essential to prevent skin damage if
periods of sun exposure long enough to produce ery-
thema are planned. One Australian study showed that
normal SPF usage over summer did not significantly
affect 25OHD concentrations.18 For incidental sun
exposures of less than 10 minutes duration, it may be
better to omit sunscreen. Short exposures are more
efficient at producing vitamin D. Once previtamin D3
and vitamin D3 have been formed, continued exposure
to sunlight results in their degradation to relatively
inert over irradiation products.4 It therefore appears
prudent to recommend exposure of hands, face and
arms to 5–15 minutes of sunlight 4–6 times a week,
with the greatest frequency recommended for the
elderly and dark skinned populations. Data collected in
New Zealand indicate that exposure to sunshine for 30
minutes a day for 1 month during Spring produced a
30% increase in serum 25OHD levels in elderly men
and women.19
Vitamin D supplementation
Oral preparations such as ergocalciferol (D2) and
cholecalciferol (D3) are available in Australia to treat
vitamin D deficiency. Twelve calcium supplements
contain vitamin D, all but one contain cholecalciferol,
however, the levels are quite low ranging from
32–200 IU per tablet. Halibut liver oil tablets provide
4000 IU per capsule and although these are economi-
cal (~0.08 cents/capsule) they do contain vitamin A
(4000 IU) which may not be beneficial for everyone.
The only pure vitamin D preparation in Australia is
Ostelin 1000, which contains ergocalciferol (D2)
(1000 IU at ~24 cents/capsule). Vitamin D status is
assessed by measurement of blood 25OHD concen-
trat ions,  not 1,25(OH)2D. Treatment with
ergocalciferol does not appear to increase plasma
25OHD levels (including both 25OHD2 and 25OHD3)
as effectively as supplementation with cholecalcif-
erol.20 It is not clear, however, how much of the
apparent increased effectiveness of D3 above D2 is
due to the sensitivity of the assay. The assay is more
sensitive to D3 than D2.21
Treatment of vitamin D deficiency
Vitamin D is stored in fat and muscle and is slowly
released, particularly during winter.22 In vitamin D defi-
cient patients, it is necessary to replete vitamin D stores.
While the daily requirement for vitamin D is 400–600 IU
per day, a much larger dose is used to treat vitamin D
deficient patients. As vitamin D is fat soluble with a half-
life >3 weeks, large doses are needed before changes in
serum 25OHD are seen. High dosages of vitamin D
(3000–5000 IU per day for 6–12 weeks [Ostelin]) may be
used to replete body stores. Oral doses of 10 000 IU per
day over 90 days have been shown to increase serum
25OHD levels to 86 nmol/L in postmenopausal women at
latitude 34°S.23 Higher doses of 50 000–500 000 IU orally
or 600 000 IU intramuscularly can effectively treat vitamin
D deficiency, however, they are not currently available in
Australia and there is the possibility of inducing hypercal-
caemia/hypercalciuria. Serum 25OHD levels should be
checked at 3–4 monthly intervals to ensure adequacy of
replacement. Calcitriol, the bioactive preparation of
vitamin D, is not recommended for treating patients with
simple vitamin D deficiency. This agent has a narrow
therapeutic window and may result in significant hyper-
calcaemia. Moreover, changes in serum 25OHD levels
are not a reflection of the calcitriol therapy.
Toxicity
Vitamin D toxicity cannot be caused by prolonged exposure
of the skin to UV light but may occur with excess oral intake
through supplementation.24 Vitamin D intoxication may
cause anorexia, nausea, weakness, weight loss, polyuria,
constipation, headache, depression, vague aches, stiffness,
soft tissue calcification, nephrocalcinosis, hypertension,
anaemia, hypercalcaemia, acidosis and irreversible renal and
heart failure.25 It should be noted that although vitamin D is
toxic, relatively high doses are safe with no signs of toxicity
at doses up to 4000 IU per day.26 Although there is data indi-
cating that high dose 300 000 IU injections given at intervals
of at least a few months cause little evidence of toxicity,27
such supraphysiological doses are yet to be established as
safe. Cod liver oil, in addition to containing vitamin D, con-
tains vitamin A which can also be toxic at high doses.
Effectiveness of vitamin D supplementation
The greatest therapeutic effect of vitamin D supplemen-
tation is seen in high risk individuals who demonstrate
decreases in bone densities, ranging from 0–4% in
vitamin D insufficient patients to 10–40% in vitamin D
deficient patients with osteomalacia.28,29 The pivotal trial
relating fracture reduction in a high risk group treated
with vitamin D3 supplementation (800 IU of cholecalcif-
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erol for 18 months) was published in 1992 and demon-
strated a 41% reduction in hip fractures in elderly
women in residential care establishments.30 More
recently, in a double blind randomised controlled trial,
oral cholecalciferol 100 000 IU administered every 4
months for 5 years, reduced the risk of first hip, wrist,
forearm or vertebral fracture in community dwelling
persons by 33% compared with placebo.31 Other
studies in community dwelling individuals and lower
vitamin D doses have not shown fracture reductions.32
It is unlikely that vitamin D supplementation has
any role in vitamin D replete individuals, although the
optimal level of serum 250HD is not precisely known
(but may be above 60 nmol/L). Many studies have been
undertaken to determine whether vitamin D therapies
can prevent or treat postmenopausal osteoporosis. The
varying increases in bone densities and reduction in
fracture rates may be attributed to differences in pre-
treatment PTH and vitamin D levels. A comprehensive
meta-analysis suggests that vitamin D reduces the risk
of vertebral fractures by 37% (RR: 0.63; 95% CI:
0.45–0.88, p<0.01) with no significant reduction in non-
vertebral fractures (RR: 0.77; 95% CI: 0.57–1.04,
p<0.09).33 Most studies have utilised a combination of
vitamin D and calcium supplementation therefore ade-
quate dietary calcium may be required in conjunction
with adequate vitamin D to reduce fracture rate. 
Conclusion 
Treatment with a vitamin D supplement with or without
screening should be considered for groups at greatest risk
of vitamin D deficiency as listed in Table 4. The amount of
recommended dietary vitamin D is the best estimate
based on current available evidence, acknowledging that
more data is required to make specific recommendations
for different population groups. Accordingly the estimated
amount of dietary or supplemental vitamin D required to:
prevent deficiency 200–600 IU, reduce fracture risk in the
elderly 800–1000 IU, and to treat deficiency 3000–5000 IU
per day for at least 1 month.
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Table 4. Recommendations 
High risk groups
• elderly people, particularly in residential care
• people with skin cancers or skin related conditions
where avoidance of sunlight is required
• dark skinned people, particularly pregnant or
veiled women
• individuals presenting with osteoporosis or
minimal trauma fractures
• patients with malabsorption
Optimal blood test
• 25OHD (Diasorin, radioimmunoassay kit)
Good dietary sources of vitamin D
• fatty fish, eg. mackerel and herring,
margarine (fortified)
Minimum sun exposure to prevent deficiency
• exposure of hands, face and arms to 5–15
minutes of sunlight 4–6 times per week
• the elderly or those with dark skin require
the greater frequency of exposure
Amount of dietary vitamin D required to
prevent deficiency
• between 200 IU (<50 years) – 600 IU (>70
years) per day
Amount of vitamin D supplementation required
to reduce fracture risk in the elderly
• between 800–1000 IU per day
Amount of vitamin D required to treat deficiency
• between 3000–5000 IU per day for at least 
1 month 
• People at high risk of vitamin D deficiency include
the elderly (particularly in residential care), those
with skin conditions where avoidance of sunlight
is required, dark skinned people (particularly if
veiled), and patients with malabsorption.
• Combined vitamin D and calcium supplementation has
been shown to reduce falls and fractures in the elderly.
• Exposure of hands, face and arms to 5–15
minutes of sunlight 4–6 times a week is recom-
mended, with the greatest frequency for those
who are older and have dark skin. If this is not pos-
sible then a vitamin D supplement of at least 400
IU per day is recommended. Note: deliberate
exposure to sunlight between 10 am and 3 pm in
the summer months is not advised.
• In the case of established vitamin D deficiency
cases, supplementation with between 3000-5000
IU per day for at least 1 month is required to
replete body stores.
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